In these models, an upregulation of the ERα-p-Ser118 following an activation of growth factor pathway signalling (EGFR, IGFR) and the activation of MAP kinase has been demonstrated when tumours started to grow despite letrozole (Chen et al, 2006). The gene discussed is EGFR; the disease is neoplasm.